A Phase 1 interventional study of PF-03716539 and PF-03716539 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-02.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
(BMI) of approximately 18 to 30 kg/m2. Total body weight >50 kg (110 lbs).
Exclusion Criteria:
Pregnant or nursing females. females of . Evidence or history of hematological, renal (including kidney stones), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at screening.
Treatment with an drug within 30 days (or determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-03716539 crossover, single dose escalation (doses subject to change).
Drug: PF-03716539 · Other: Placebo
PF-03716539 crossover, single dose escalation (doses subject to change).
Drug: PF-03716539 · Other: Placebo
Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
Drug: Midazolam · Drug: Midazolam + PF-03716539 (100 mg) · Drug: Midazolam + PF-03716539 (50 mg)
Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
Drug: Darunavir · Drug: Darunavir + PF-03716539
Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
Drug: Maraviroc · Drug: Maraviroc +PF-03716539
Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
Drug: Maraviroc · Drug: Maraviroc +PF-03716539
PF-03716539 10 mg oral solution, single dose
PF-03716539 25 mg oral solution, single dose
PF-03716539 3 mg oral solution, single dose
Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
PF-03716539 100 mg oral solution, single dose
PF-03716539 200 mg oral solution, single dose
PF-03716539 50 mg oral solution, single dose
Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
Midazolam 1 mg IV, single dose
Drug page: Midazolam
Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
Drug page: Midazolam
Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
Drug page: Darunavir
Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
Also known as: Selzentry
Drug page: Maraviroc
Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
Also known as: Selzentry
Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
Also known as: Selzentry
Drug page: Maraviroc
Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
Also known as: Selzentry
To evaluate the safety and tolerability of escalating single oral doses of PF 03716539 administered as Extemporaneous Powder for Solution (EPS) in healthy adult subjects.
Time frame: 27 days
To explore the pharmacokinetics of escalating single oral doses of PF 03716539 in healthy adult subjects.
Time frame: 6 days
To assess the potency of PF 03716539 for CYP3A4 inhibition utilizing single dose IV midazolam as a probe substrate for CYP3A4/5.
Time frame: 6 days
To evaluate the potential of PF 03716539 to enhance or "boost" the pharmacokinetics of both darunavir and maraviroc.
Time frame: 8 days
The record gives a start of Oct 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Darunavir · Maraviroc